TY  - JOUR
TI  - Pharmacologic Therapy That Simulates Conditioning for Cardiac Ischemic/Reperfusion Injury.
EP  - 96
AV  - public
SP  - 83
VL  - 19
Y1  - 2014/01//
N1  - © The Author(s) 2013. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).
IS  - 1
ID  - discovery1409039
N2  - Cardiovascular disease remains a leading cause of deaths due to noncommunicable diseases, of which ischemic heart disease forms a large percentage. The main therapeutic strategy to treat ischemic heart disease is reperfusion that could either be medical or surgical. However, reperfusion following ischemia is known to increase the infarct size further. Newer strategies such as ischemic preconditioning (IPC), ischemic postconditioning, and remote IPC have been shown to condition the myocardium to ischemia-reperfusion injury and thus reduce the final infarct size. Research over the past 3 decades has deepened our understanding of cellular and subcellular pathways that mediate ischemia-reperfusion injury. This in turn has resulted in the development of several pharmacological agents that act as conditioning agents, which reduce the final myocardial infarct size following ischemia-reperfusion. This review discusses many of these agents, their mechanisms of action, and the animal and clinical evidence behind them.
UR  - http://dx.doi.org/10.1177/1074248413499973
JF  - J Cardiovasc Pharmacol Ther
KW  - acute myocardial infarction
KW  -  cardiac pharmacology
KW  -  heart disease
KW  -  ischemia?reperfusion injury
A1  - Sivaraman, V
A1  - Yellon, DM
ER  -